606 completed, 98 recruiting, 66 unknown, 58 terminated. 971 Phase 2, 153 Phase 1, 127 Phase 3.
Follow Overweight: new trials by email Literature Review of Overweight trials Research Report on Overweight
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oxytocin for Respiratory Compromise and Hypoventilation Induced by Drugs Intranasal Oxytocin 40 i.u., Intranasal Placebo Spray - Obesity & Overweight, Respiratory Depression | Phase 2 | Not yet recruiting | George Washington University | 100 | 2027-05-15 | 2026-10-29 |
| Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer Semaglutide (Wegovy®) - Breast Cancer (Early Breast Cancer), Obesity | Phase 2 | Not yet recruiting | Aarhus University Hospital | 32 | 2027-03-01 | 2026-11-02 |
| Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults LUM-201, Placebo, Semagludtide - Obesity & Overweight | Phase 2 | Not yet recruiting | Lumos Pharma | 202 | 2027-02-15 | 2026-08-10 |
| Semaglutide for Low Back Pain Semaglutide (administered by PDS290 pen-injector), Placebo (administered by PDS290 pen-injector) - Lower Back Pain, Obesity (BMI>30) | Phase 2 | Not yet recruiting | Washington University School of Medicine | 250 | 2027-02-01 | 2026-07-28 |
| Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer Semaglutide (Wegovy) weekly injection, LNG-IUD (Progestin), Structured Weight Loss Program - Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia | Phase 2 | Not yet recruiting | The Methodist Hospital Research Institute | 48 | 2027-01-01 | 2026-10-01 |
| Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer Tirzepatide - Endometrial Cancer, Endometrial Intraepithelial Neoplasia | Phase 2 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 40 | 2027-01-01 | 2026-09-28 |
| Supplementation of Gut-brain Axis (GLP-1)-Activating Carbohydrates for Increasing Satiety in Adolescents With Obesity gut-brain axis (GLP-1)-activating food carbohydrate, starch-based placebo control (commercial maltodextrin) - Obesity & Overweight | Phase 2 | Not yet recruiting | Indiana University | 62 | 2027-01-01 | 2026-10-21 |
| Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High - Type 2 Diabetes, High Blood Pressure | Phase 1 / Phase 2 | Withdrawn | ARKAY Therapeutics | 2026-12-10 | 2026-07-16 | |
| Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity Tirzepatide - Type 1 Diabetes Mellitus, Overweight and Obesity | Phase 2 | Not yet recruiting | Royal North Shore Hospital | 40 | 2026-12-01 | 2025-07-29 |
| VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway Vericiguat 10 MG, Placebo, Insulin Sensitivity Test - Cardiovascular Diseases, Insulin Sensitivity/Resistance | Phase 2 | Not yet recruiting | University of Alabama at Birmingham | 200 | 2026-12-01 | 2026-01-23 |
| HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide Calcium-HMB Plus Vitamin D3, Matching placebo - Type 2 Diabetes Mellitus (T2DM), Sarcopenia | Phase 2 | Not yet recruiting | Vanderbilt University Medical Center | 90 | 2026-12-01 | 2026-08-28 |
| IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity IGOB131, Dextrin - Obesity & Overweight | Phase 2 | Not yet recruiting | University of Yaounde 1 | 80 | 2026-12-01 | 2026-10-20 |
| Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy Semaglutide (Rybelsus®), Placebo - Duchenne Muscular Dystrophy (DMD) | Phase 1 / Phase 2 | Recruiting | Vanderbilt University Medical Center | 30 | 2026-12-01 | 2026-11-12 |
| A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight Petrelintide, Enicepatide, Petrelintide-matching Placebo - Obesity or Overweight | Phase 2 | Not yet recruiting | Hoffmann-La Roche | 486 | 2026-11-30 | 2026-11-03 |
| A Study to Evaluate Efficacy and Safety of BGM1812 Injection in Overweight or Obese Participants Without Diabetes BGM1812 injection / plcaebo - Overweight or Obese Participants Without Diabetes | Phase 2 | Not yet recruiting | BrightGene Bio-Medical Technology Co., Ltd. | 160 | 2026-11-30 | 2026-11-05 |
| Investigating the Effects of 24 Hour LEAP2 Infusion in Individuals With Overweight and Obesity Liver-expressed antimicrobial peptide 2, Placebo - Obesity & Overweight | Phase 1 / Phase 2 | Not yet recruiting | University Hospital, Gentofte, Copenhagen | 18 | 2026-11-30 | 2026-10-27 |
| Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity Alpha-lipoic acid, Mirabegron, Placebo - Insulin Resistance, Obesity | Phase 2 | Not yet recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 60 | 2026-11-18 | 2026-11-13 |
| A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity ecnoglutide tablet, placebo with matching dosage - Overweight , Obesity, Weight Management | Phase 2 | Not yet recruiting | Hangzhou Sciwind Biosciences Co., Ltd. | 180 | 2026-11-10 | 2026-11-10 |
| Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer Mazdutide(Dual GLP-1R/GCGR Agonist), Placebo, Levonorgestrel-releasing intrauterine system - Obesity, Overweight | Phase 2 | Not yet recruiting | Tongji Hospital | 128 | 2026-11-01 | 2026-08-24 |
| A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes LY4086940, Placebo - Obesity, Overweight | Phase 2 | Not yet recruiting | Eli Lilly and Company | 460 | 2026-11-01 | 2026-11-03 |
Showing 20 of 971. Sign in to see all of them.
Obesity (847) · Diabetes Mellitus, Type 2 (105) · Weight Loss (105) · Insulin Resistance (69) · Diabetes Mellitus (62) · Metabolic Syndrome (50) · Hypertension (42) · Motor Activity (36) · Pediatric Obesity (34) · Obesity, Morbid (31) · Prader-Willi Syndrome (31) · Non-alcoholic Fatty Liver Disease (26) · Body Weight (24) · Obesity, Abdominal (22)
Nutritional and Metabolic Diseases (968) · Overnutrition (963) · Nutrition Disorders (961) · Pathological Conditions, Signs and Symptoms (950) · Signs and Symptoms (946) · Body Weight (920) · Metabolic Diseases (248) · Glucose Metabolism Disorders (242) · Endocrine System Diseases (178) · Body Weight Changes (114) · Diabetes Mellitus (107) · Hyperinsulinism (100) · Obesity (88) · Nervous System Diseases (66)
Tirzepatide (41) · semaglutide (40) · Exercise (24) · Metformin (22) · Liraglutide (16) · Diet (15) · Topiramate (12) · Exenatide (10) · Orlistat (10) · Oxytocin (10) · Cholecalciferol (9) · Sodium Chloride (9) · empagliflozin (9) · Phentermine (8) · bupropion hydrochloride, naltrexone hydrochoride drug combination (8)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (22) · Eli Lilly and Company (21) · AstraZeneca (16) · Vanderbilt University Medical Center (15) · Massachusetts General Hospital (14) · Yale University (13) · Pfizer (12) · Mayo Clinic (10) · Novo Nordisk A/S (10) · Stanford University (10) · University of Minnesota (10) · Washington University School of Medicine (10) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (9) · Novartis Pharmaceuticals (9) · University of Colorado, Denver (9)
United States (557) · China (73) · Canada (67) · United Kingdom (36) · Australia (35) · France (29) · Germany (27) · Spain (27) · Denmark (25) · Mexico (22) · Netherlands (21) · Sweden (20) · Japan (16) · Puerto Rico (16) · Argentina (15)
Jack A Yanovski, M.D. (9) · David Meeker, MD (5) · John M Jakicic, Ph.D. (5) · Lisa Porter, MD (5) · Allison B. Goldfine, MD (4)
PMID 39952695, PMID 23703580, PMID 26210388, PMID 26589105, PMID 12150647, PMID 18753666, PMID 19741604, PMID 19853906, PMID 19889232, PMID 21070531, PMID 21720440, PMID 21816979, PMID 25091629, PMID 28059466, PMID 29718281, PMID 30122305, PMID 33029899, PMID 35112343, PMID 38365073, PMID 42014131, PMID 10480510, PMID 10523015, PMID 10560680, PMID 10868854, PMID 10963727, PMID 11238785, PMID 11245554, PMID 11304102, PMID 11411567, PMID 11433905, PMID 11443202, PMID 11556815, PMID 11565517, PMID 11565518, PMID 11832527, PMID 12105286, PMID 12126214, PMID 12523673, PMID 12622244, PMID 12684357, PMID 12805393, PMID 12833109, PMID 12841897, PMID 15030519, PMID 15070752, PMID 15112907, PMID 15168555, PMID 15273542, PMID 15333514, PMID 15380496
2023 (8), 2017 (6), 2009 (5), 2008 (3), 2014 (3), 2016 (3), R01DK049587 (3), R01DK126637 (3), 2015 (2), 2019 (2), R56DK067071 (2), U01CA150387 (2), U01DK074556 (2), UL1TR000135 (2), 1IK2CX002225-01A1 (1)